GABAergic Neurotransmission in Panic Disorder:Psychophysical and neurochemical Predictors of Therapy Outcome

Not Applicable

Recruiting

• Conditions: F41.0; F40.01; Panic disorder [episodic paroxysmal anxiety]

• Registration Number: DRKS00000615
• Lead Sponsor: Klinik für Psychiatrie und Psychotherapie, UK SH, Campus Lübeck

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-01-13
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Age: 18-60 years
Right handedness
Panic disorder (with or without agoraphobia) according to DSM-IV as primary diagnosis
PAS: 19 or greater

Exclusion Criteria

General exclusion criteria for MRI (www.mrsafety.com)
Substance dependence or abuse
Psychotic disorders
Neurological disorders or history of brain trauma
Severe chronic somatic disorders
24h before measurement: Alcohol, Nicotine, Sleep deprivation, Drugs and psychoactive substances, particularly tranquilizer, sleep medication (except of SSRI in a stable dose since 6 weeks)
Control subjects: History of psychiatric disorders according to SCID screening

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical: Change of panic symptoms according to Panic and Agroraphobia Scale (PAS: total score) after 6 weeks/12 sessions of Behavior Therapy<br>MR-Spectroscopy: Change of cortical GABA concentration (IU) after 6 weeks/12 sessions of Behavior Therapy<br>Psychophysics: Change of visual surround suppression effect ('point of subjective equivalence' in %) after 6 weeks/12 sessions of Behavior Therapy

Secondary Outcome Measures

Name	Time	Method
Clinical: Symptom change according to Hamilton Anxiety Scale (HAM-A; total score) and Hamilton Depression Scale (HAM-D; total score) after 6 weeks/12 sessions of Behavior Therapy